Gewinn- und Verlustrechnung von Pfizer Inc.

Pfizer remains significantly undervalued, demonstrating robust profitability and offering an attractive forward dividend yield above 6%. PFE's diversified product roadmap and disciplined capital allocation help offset LOE uncertainties and COVID revenue declines, stabilizing business variability. Oncology pipeline progress, bolstered by the Seagen acquisition, provides credible growth pathways beyond early clinical stages, anchoring the long-term growth optionality.

Dividend investors have had plenty to cheer in 2026. Pfizer (NYSE:PFE | PFE Price Prediction) is up 19.3% year to date, Chevron (NYSE:CVX) has surged 38.76%, and AbbVie (NYSE:ABBV) has added 19.16%.

Big-league hedge funds have been taking interest in shares of Pfizer (NYSE:PFE | PFE Price Prediction) of late, with recent 13F filings revealing significant buying activity among the smart money crowd.

Among U.S. large-cap drugmakers, one name has clearly outrun the pack in 2026 so far.

Merck & Company, Inc‘s (NYSE:MRK) latest commitment to personalized cancer vaccines is sending a message that extends well beyond Moderna, Inc. (NASDAQ:MRNA).

PFE aims to break into the obesity market with berobenatide, a potential monthly treatment designed to compete with leading GLP-1 therapies.

Several stocks have recently seen notable insider buys from CEOs, including a $10 million dollar bet from a semiconductor favorite.

Gateway Wealth Partners LLC lowered its position in Pfizer Inc. (NYSE: PFE) by 54.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,883 shares of the biopharmaceutical company's stock after selling 23,708 shares during the period. Gateway Wealth Partners LLC's

Bruce Berkowitz's Fairholme Capital disclosed in its Q2 2026 13F filing that 18,182,367 shares of St.

Pfizer remains a cautious Buy, trading near intrinsic value with an expected 10% annual return, primarily from its high dividend yield. PFE faces significant headwinds: a looming patent cliff, a stretched balance sheet, and questions about the sustainability of its dividend and growth prospects. Management projects high single-digit revenue CAGR post-2028, driven by acquisitions, pipeline progress, and aggressive cost-saving initiatives, though analysts remain skeptical.